Table 1.

Summary of studies demonstrating clinical utility of ctDNA-CSF in CNS disease.

Study	Tumor types	Number of samples	Assay method	Analyte	Mutation detection rate
De Mattos-Arruda et al. PMID: 26554728	Breast, lung, GBM	n = 12	Targeted sequencing	CSF	60%
				Plasma	55%
Pentsova et al. PMID: 27161972	Advanced solid tumors and primary CNS tumors	n = 32	Targeted sequencing	CSF	60–75%
Li et al. PMID: 29346604	NSCLC	n = 26	Targeted sequencing	CSF	100%
				Plasma	73%
Bettegowda et al. PMID: 24553385	Advanced solid tumors and primary CNS tumors	n = 640	Targeted sequencing	Plasma	>75% for most solid tumors
Zill et al. PMID: 29776953	Advanced solid tumors and primary CNS tumors	n = 21,807	Targeted sequencing	Plasma	51–93%
Wang et al. PMID: 26195750	Primary CNS tumors	n = 35	Targeted sequencing	CSF	74%
Miller et al. PMID: 30675060	Primary CNS tumors	n = 85	Targeted sequencing	CSF	50%
				Plasma	0%
von Baumgarten et al. PMID: 31903155	Advanced solid tumors	n=27	Targeted sequencing	CSF	74%
Martinez-Ricarte et al. PMID: 29615461	Primary CNS tumors	n = 20	Targeted sequencing	CSF	79%
Momtaz et al. PMID: 27863426	Advanced melanoma	n = 11	Digital droplet PCR (ddPCR)	CSF	55%
Schwaederle et al. PMID: 26848768	Advanced solid tumors and GBM	n = 171	Targeted Sequencing	Plasma	65%
Piccioni et al. PMID: 30855176	Primary CNS tumors	n = 419	Targeted sequencing	Plasma	50%
Mouliere et al. PMID: 30401727	Primary CNS tumors	n = 13	Shallow whole genome sequencing	CSF	39%
				Plasma
Pan et al. PMID: 25605683	Advanced solid tumors and primary CNS tumors	n = 7	ddPCR	CSF	86%
			Targeted sequencing	Plasma
Bobillo et al. PMID: 32079701	B-cell lymphoma	n = 19	ddPCR	CSF	32%
			Targeted sequencing	Plasma
Huang et al. PMID: 31161597	Lung adenocarcinoma	n = 35	ddPCR	CSF	50–75%
				Plasma